Oxford Biomedica plc (LON:OXB – Get Free Report)’s stock price reached a new 52-week high on Wednesday . The company traded as high as GBX 395 ($5.16) and last traded at GBX 363.50 ($4.75), with a volume of 180664 shares traded. The stock had previously closed at GBX 383.50 ($5.01).
Analysts Set New Price Targets
Separately, Deutsche Bank Aktiengesellschaft increased their price target on shares of Oxford Biomedica from GBX 250 ($3.26) to GBX 380 ($4.96) and gave the company a “hold” rating in a research report on Tuesday, September 24th.
Get Our Latest Analysis on OXB
Oxford Biomedica Stock Performance
Oxford Biomedica Company Profile
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems.
Further Reading
- Five stocks we like better than Oxford Biomedica
- What is the Nasdaq? Complete Overview with History
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- 3 Healthcare Dividend Stocks to Buy
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- 3 Stocks to Consider Buying in October
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related companies with MarketBeat.com's FREE daily email newsletter.